Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Sep;35(9):1760–1764. doi: 10.1128/aac.35.9.1760

Beta-lactamase of Mycobacterium fortuitum: kinetics of production and relationship with resistance to beta-lactam antibiotics.

L Fattorini 1, G Scardaci 1, S H Jin 1, G Amicosante 1, N Franceschini 1, A Oratore 1, G Orefici 1
PMCID: PMC245264  PMID: 1952844

Abstract

The kinetics of both intracellular and extracellular beta-lactamase production and the relationship between extracellular enzyme and in vitro susceptibility of Mycobacterium fortuitum to beta-lactam antibiotics have been studied. To this end we used a panel of stable nitrosoguanidine-induced mutants of M. fortuitum derived from the parental strain ATCC 19542 and differing in beta-lactamase production from 0.0001 to 278 U/liter in Mueller-Hinton broth. For overproducers of beta-lactamase (mutants A188, B180, C207, D316, and E31), MICs of benzylpenicillin, amoxicillin, ampicillin, and cephaloridine progressively increased with the amount of enzyme released into the medium, whereas MICs of imipenem and cefoxitin did not. The resistance of the mutants to amoxicillin was reduced up to 32-fold by clavulanic acid, whereas that to ampicillin was reduced 8-fold by sulbactam. These data suggest that the enzyme participated in the mechanisms of resistance to the beta-lactam antibiotics. However, for a mutant of M. fortuitum (gamma 27) with virtually nonexistent beta-lactamase production, the antibiotics still had relatively high MICs (for instance, benzylpenicillin and cephaloridine had MICs of 64 and 32 micrograms/ml, respectively). This suggests that, aside from beta-lactamase production, other mechanisms such as cell wall permeability and/or affinity for penicillin-binding proteins could coexist in M. fortuitum and explain its natural resistance to beta-lactam antibiotics.

Full text

PDF
1760

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amicosante G., Franceschini N., Segatore B., Oratore A., Fattorini L., Orefici G., Van Beeumen J., Frere J. M. Characterization of a beta-lactamase produced in Mycobacterium fortuitum D316. Biochem J. 1990 Nov 1;271(3):729–734. doi: 10.1042/bj2710729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casal M. J., Rodriguez F. C., Benavente M. C. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole. Antimicrob Agents Chemother. 1985 Feb;27(2):282–283. doi: 10.1128/aac.27.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Casal M., Rodríguez F., Gutierrez J., Ruiz P., Benavente M. C., Villalba R., Moreno G. Promising new drugs in the treatment of tuberculosis and mycobacteriosis. J Chemother. 1989 Feb;1(1):39–45. doi: 10.1080/1120009x.1989.11738862. [DOI] [PubMed] [Google Scholar]
  4. Choubey D., Gopinathan K. P. Characterization of beta-lactamase from Mycobacterium butyricum ATCC 19979. Biochem Int. 1986 Feb;12(2):207–214. [PubMed] [Google Scholar]
  5. Cullmann W., Dick W., Dalhoff A. Nonspecific induction of beta-lactamase in Enterobacter cloacae. J Infect Dis. 1983 Oct;148(4):765–765. doi: 10.1093/infdis/148.4.765. [DOI] [PubMed] [Google Scholar]
  6. Cynamon M. H., Palmer G. S. In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins. Antimicrob Agents Chemother. 1982 Dec;22(6):1079–1081. doi: 10.1128/aac.22.6.1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cynamon M. H., Palmer G. S. In vitro susceptibility of Mycobacterium fortuitum to amoxicillin or cephalothin in combination with clavulanic acid. Antimicrob Agents Chemother. 1983 Jun;23(6):935–937. doi: 10.1128/aac.23.6.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fattorini L., Amicosante G., Fiorentino D., Franceschini N., Di Marzio L., Oratore A., Orefici G. Inhibitors and inactivators of beta-lactamase from Mycobacterium fortuitum. J Chemother. 1989 Oct;1(5):293–297. doi: 10.1080/1120009x.1989.11738911. [DOI] [PubMed] [Google Scholar]
  9. Kaneda S., Yabu K. Purification and some properties of beta-lactamase from Mycobacterium smegmatis. Microbiol Immunol. 1983;27(2):191–193. doi: 10.1111/j.1348-0421.1983.tb03583.x. [DOI] [PubMed] [Google Scholar]
  10. Kasik J. E., Peacham L. Properties of beta-lactamases produced by three species of mycobacteria. Biochem J. 1968 May;107(5):675–682. doi: 10.1042/bj1070675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nash D. R., Wallace R. J., Jr, Steingrube V. A., Udou T., Steele L. C., Forrester G. D. Characterization of beta-lactamases in Mycobacterium fortuitum including a role in beta-lactam resistance and evidence of partial inducibility. Am Rev Respir Dis. 1986 Dec;134(6):1276–1282. doi: 10.1164/arrd.1986.134.5.1276. [DOI] [PubMed] [Google Scholar]
  12. Udou T., Mizuguchi Y., Yamada T. Biochemical mechanisms of antibiotic resistance in a clinical isolate of Mycobacterium fortuitum. Presence of beta-lactamase and aminoglycoside-acetyltransferase and possible participation of altered drug transport on the resistance mechanism. Am Rev Respir Dis. 1986 Apr;133(4):653–657. doi: 10.1164/arrd.1986.133.4.653. [DOI] [PubMed] [Google Scholar]
  13. Wallace R. J., Jr, Swenson J. M., Silcox V. A., Bullen M. G. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis. 1985 Sep;152(3):500–514. doi: 10.1093/infdis/152.3.500. [DOI] [PubMed] [Google Scholar]
  14. Wallace R. J., Jr, Swenson J. M., Silcox V. A., Good R. C., Tschen J. A., Stone M. S. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983 Jul-Aug;5(4):657–679. doi: 10.1093/clinids/5.4.657. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES